Alasdair King | Executive Director
Merck Animal Health

Alasdair King, Executive Director, Merck Animal Health

Alasdair King qualified as a veterinary surgeon from Glasgow University in 1990.  After 11 years in mixed practice he joined Intervet UK as livestock veterinary advisor.  Amongst other roles in the UK, he took on responsibility for company pharmacovigilance as the National PV Manager, and developed the UK focus on transboundary and emerging diseases as Government Liaison Officer.  During this time he was responsible for working on the avian influenza vaccine banks and led the company response in the UK to the Bluetongue serotype 8 outbreak, working with the government to establish a vaccine roll out plan.  In addition he was responsible for communications with all forms of media within MSD Animal Health and was part of the crisis management team.  In 2012 he joined the Institutional Sales Department of MSD Animal Health, based in Boxmeer, with the main responsibility for FMD.
Now the Executive Director of International Veterinary Health, he has developed the emergence newsletter and website to provide information on emerging and transboundary diseases, as well as being host of the emergence podcast. He works with a number of governments and organisations on disease control plans and strategies, with a focus on vaccine accessibility and education, alongside surveillance and monitoring. He has worked with the WHO, WOAH, and FAO on a number of projects, participating in working groups on such subjects as rabies elimination, FMD vaccine pre-qualification, training for para-professionals in developing countries, and access to medicines.

Appearances:



Day 2 - Wednesday 15th October @ 15:15

Field Implementation Strategies in Wildlife and Livestock

  • Practical aspects of wildlife vaccination programmes: oral bait for ASF in wild boar/feral pigs, lessons from classical swine fever control
  • Surveillance strategies and challenges; overcoming practical and ethical challenges in wildlife sampling, balancing active vs. passive surveillance, UK bat surveillance for rabies (APHA Weybridge)
  • Evolution of vaccine profiles from containment to eradication stages
  • Role of DIVA strategies in eradication programs
  • Case study: PPR vaccine transition from live to killed vaccines

Day 2 - Wednesday 15th October @ 16:00

Non-Technical Barriers to Vaccine Adoption in Livestock and Companion Animals

last published: 07/May/25 13:55 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2025

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com

 

Otto Squire
Otto.Squire@terrapinn.com

 

TO SPEAK


Anna Hindley-Skelt
Anna.Hindley-Skelt@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.